286 related articles for article (PubMed ID: 31892343)
21. Clinical case study meets population cohort: identification of a BRCA1 pathogenic founder variant in Orcadians.
Kerr SM; Cowan E; Klaric L; Bell C; O'Sullivan D; Buchanan D; Grzymski JJ; van Hout CV; Tzoneva G; Shuldiner AR; Wilson JF; Miedzybrodzka Z
Eur J Hum Genet; 2023 May; 31(5):588-595. PubMed ID: 36927983
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of two population screening programmes for
Cousens NE; Tiller J; Meiser B; Barlow-Stewart K; Rowley S; Ko YA; Mahale S; Campbell IG; Kaur R; Bankier A; Burnett L; Jacobs C; James PA; Trainer A; Neil S; Delatycki MB; Andrews L
BMJ Open; 2021 Jun; 11(6):e041186. PubMed ID: 34172541
[TBL] [Abstract][Full Text] [Related]
23. Prevalence and spectrum of BRCA germline variants in mainland Chinese familial breast and ovarian cancer patients.
Kim YC; Zhao L; Zhang H; Huang Y; Cui J; Xiao F; Downs B; Wang SM
Oncotarget; 2016 Feb; 7(8):9600-12. PubMed ID: 26848529
[TBL] [Abstract][Full Text] [Related]
24. Case Review: Whole-Exome Sequencing Analyses Identify Carriers of a Known Likely Pathogenic Intronic
Alenezi WM; Fierheller CT; Revil T; Serruya C; Mes-Masson AM; Foulkes WD; Provencher D; El Haffaf Z; Ragoussis J; Tonin PN
Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456503
[TBL] [Abstract][Full Text] [Related]
25. Next Generation Sequencing Reveals High Prevalence of BRCA1 and BRCA2 Variants of Unknown Significance in Early-Onset Breast Cancer in African American Women.
Ricks-Santi L; McDonald JT; Gold B; Dean M; Thompson N; Abbas M; Wilson B; Kanaan Y; Naab TJ; Dunston G
Ethn Dis; 2017; 27(2):169-178. PubMed ID: 28439188
[TBL] [Abstract][Full Text] [Related]
26. BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts.
Lucas AL; Frado LE; Hwang C; Kumar S; Khanna LG; Levinson EJ; Chabot JA; Chung WK; Frucht H
Cancer; 2014 Jul; 120(13):1960-7. PubMed ID: 24737347
[TBL] [Abstract][Full Text] [Related]
27. Genetic variants associated with breast cancer risk for Ashkenazi Jewish women with strong family histories but no identifiable BRCA1/2 mutation.
Rinella ES; Shao Y; Yackowski L; Pramanik S; Oratz R; Schnabel F; Guha S; LeDuc C; Campbell CL; Klugman SD; Terry MB; Senie RT; Andrulis IL; Daly M; John EM; Roses D; Chung WK; Ostrer H
Hum Genet; 2013 May; 132(5):523-36. PubMed ID: 23354978
[TBL] [Abstract][Full Text] [Related]
28. Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women.
Comen E; Davids M; Kirchhoff T; Hudis C; Offit K; Robson M
Breast Cancer Res Treat; 2011 Aug; 129(1):185-90. PubMed ID: 21394499
[TBL] [Abstract][Full Text] [Related]
29. Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers.
Im KM; Kirchhoff T; Wang X; Green T; Chow CY; Vijai J; Korn J; Gaudet MM; Fredericksen Z; Shane Pankratz V; Guiducci C; Crenshaw A; McGuffog L; Kartsonaki C; Morrison J; Healey S; Sinilnikova OM; Mai PL; Greene MH; Piedmonte M; Rubinstein WS; ; Hogervorst FB; Rookus MA; Collée JM; Hoogerbrugge N; van Asperen CJ; Meijers-Heijboer HE; Van Roozendaal CE; Caldes T; Perez-Segura P; Jakubowska A; Lubinski J; Huzarski T; Blecharz P; Nevanlinna H; Aittomäki K; Lazaro C; Blanco I; Barkardottir RB; Montagna M; D'Andrea E; ; Devilee P; Olopade OI; Neuhausen SL; Peissel B; Bonanni B; Peterlongo P; Singer CF; Rennert G; Lejbkowicz F; Andrulis IL; Glendon G; Ozcelik H; ; Toland AE; Caligo MA; ; Beattie MS; Chan S; ; Domchek SM; Nathanson KL; Rebbeck TR; Phelan C; Narod S; John EM; Hopper JL; Buys SS; Daly MB; Southey MC; Terry MB; Tung N; Hansen TV; Osorio A; Benitez J; Durán M; Weitzel JN; Garber J; Hamann U; ; Peock S; Cook M; Oliver CT; Frost D; Platte R; Evans DG; Eeles R; Izatt L; Paterson J; Brewer C; Hodgson S; Morrison PJ; Porteous M; Walker L; Rogers MT; Side LE; Godwin AK; Schmutzler RK; Wappenschmidt B; Laitman Y; Meindl A; Deissler H; Varon-Mateeva R; Preisler-Adams S; Kast K; Venat-Bouvet L; Stoppa-Lyonnet D; Chenevix-Trench G; Easton DF; Klein RJ; Daly MJ; Friedman E; Dean M; Clark AG; Altshuler DM; Antoniou AC; Couch FJ; Offit K; Gold B
Hum Genet; 2011 Nov; 130(5):685-99. PubMed ID: 21597964
[TBL] [Abstract][Full Text] [Related]
30. Identification of Recurrent Variants in
Jiang Y; Tian T; Yu C; Zhou W; Yang J; Wang Y; Wen Y; Chen J; Dai J; Jin G; Ma H; Shen H; Hu Z
Biomed Res Int; 2020; 2020():6739823. PubMed ID: 32879886
[No Abstract] [Full Text] [Related]
31. Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants.
Momozawa Y; Sasai R; Usui Y; Shiraishi K; Iwasaki Y; Taniyama Y; Parsons MT; Mizukami K; Sekine Y; Hirata M; Kamatani Y; Endo M; Inai C; Takata S; Ito H; Kohno T; Matsuda K; Nakamura S; Sugano K; Yoshida T; Nakagawa H; Matsuo K; Murakami Y; Spurdle AB; Kubo M
JAMA Oncol; 2022 Jun; 8(6):871-878. PubMed ID: 35420638
[TBL] [Abstract][Full Text] [Related]
32. Hereditary cancer screening: Case reports and review of literature on ten Ashkenazi Jewish founder mutations.
Cox DM; Nelson KL; Clytone M; Collins DL
Mol Genet Genomic Med; 2018 Nov; 6(6):1236-1242. PubMed ID: 30152102
[TBL] [Abstract][Full Text] [Related]
33. Discovery of BRCA1/BRCA2 founder variants by haplotype analysis.
Kwon WK; Jang HJ; Lee JE; Park YH; Ryu JM; Yu J; Jang JH; Kim JW
Cancer Genet; 2022 Aug; 266-267():19-27. PubMed ID: 35671604
[TBL] [Abstract][Full Text] [Related]
34. Double heterozygotes of BRCA1/BRCA2 and mismatch repair gene pathogenic variants: case series and clinical implications.
Laish I; Friedman E; Levi-Reznick G; Kedar I; Katz L; Levi Z; Halpern N; Parnasa S; Abu-Shatya A; Half E; Goldberg Y
Breast Cancer Res Treat; 2021 Aug; 188(3):685-694. PubMed ID: 34086170
[TBL] [Abstract][Full Text] [Related]
35. Spectrum and frequencies of BRCA1/2 mutations in Bulgarian high risk breast cancer patients.
Dodova RI; Mitkova AV; Dacheva DR; Hadjo LB; Vlahova AI; -Hadjieva MST; Valev SS; Caulevska MM; Popova SD; Popov IE; Dikov TI; Sedloev TA; Ionkov AS; Timcheva KV; Christova SL; Kremensky IM; Mitev VI; Kaneva RP
BMC Cancer; 2015 Jul; 15():523. PubMed ID: 26183948
[TBL] [Abstract][Full Text] [Related]
36. BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry.
Friebel TM; Andrulis IL; Balmaña J; Blanco AM; Couch FJ; Daly MB; Domchek SM; Easton DF; Foulkes WD; Ganz PA; Garber J; Glendon G; Greene MH; Hulick PJ; Isaacs C; Jankowitz RC; Karlan BY; Kirk J; Kwong A; Lee A; Lesueur F; Lu KH; Nathanson KL; Neuhausen SL; Offit K; Palmero EI; Sharma P; Tischkowitz M; Toland AE; Tung N; van Rensburg EJ; Vega A; Weitzel JN; Collaborators GS; Hoskins KF; Maga T; Parsons MT; McGuffog L; Antoniou AC; Chenevix-Trench G; Huo D; Olopade OI; Rebbeck TR
Hum Mutat; 2019 Oct; 40(10):1781-1796. PubMed ID: 31112363
[TBL] [Abstract][Full Text] [Related]
37. Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members.
Thomassen M; Blanco A; Montagna M; Hansen TV; Pedersen IS; Gutiérrez-Enríquez S; Menéndez M; Fachal L; Santamariña M; Steffensen AY; Jønson L; Agata S; Whiley P; Tognazzo S; Tornero E; Jensen UB; Balmaña J; Kruse TA; Goldgar DE; Lázaro C; Diez O; Spurdle AB; Vega A
Breast Cancer Res Treat; 2012 Apr; 132(3):1009-23. PubMed ID: 21769658
[TBL] [Abstract][Full Text] [Related]
38. Prevalence and Penetrance of BRCA1 and BRCA2 Germline Mutations in Colombian Breast Cancer Patients.
Torres D; Bermejo JL; Rashid MU; Briceño I; Gil F; Beltran A; Ariza V; Hamann U
Sci Rep; 2017 Jul; 7(1):4713. PubMed ID: 28680148
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma.
Johansson PA; Nathan V; Bourke LM; Palmer JM; Zhang T; Symmons J; Howlie M; Patch AM; Read J; Holland EA; Schmid H; Warrier S; Glasson W; Höiom V; Wadt K; Jönsson G; Olsson H; Ingvar C; Mann G; Brown KM; Hayward NK; Pritchard AL
Melanoma Res; 2019 Oct; 29(5):483-490. PubMed ID: 31464824
[TBL] [Abstract][Full Text] [Related]
40. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
